ArticlePLoS neglected tropical diseases2017
Accuracy of chimeric proteins in the serological diagnosis of chronic chagas disease - a Phase II study.
Article in PLoS neglected tropical diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Rapid diagnostic tests and ELISA for diagnosing chronic Chagas disease: Systematic revision and meta-analysis.PLoS neglected tropical diseases · 2022Pooled it
- Technological advances in the serological diagnosis of Chagas disease in dogs and cats: a systematic review.Parasites & vectors · 2022Pooled it
- Trial
- Assessment of the Performance of Indirect Immunofluorescence Assay for Chagas Disease in Dogs Using a Reference Panel of Four Chimeric Proteins.Veterinary medicine and science · 2026Article
- Diagnostic performance of the TR Chagas Bio-Manguinhos rapid test for detecting anti-Trypanosoma cruzi IgG in human samples from three Southern Cone countries.PLoS neglected tropical diseases · 2026Article
- Standardization of Serodiagnostic Methods for Trypanosoma cruzi.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Evaluation of four chimeric Trypanosoma cruzi recombinant antigens for serological diagnosis of chronic Chagas disease in dogs: a phase II study.Parasites & vectors · 2025Article
- Development of chimeric multivalent proteins for serological diagnosis of African animal trypanosomosis.Parasitology · 2025Article
- Diagnostic Performance of Chimeric Recombinant Antigens of Trypanosoma cruzi for Identifying Chagas Disease in Samples From Rio Grande do Sul.Tropical medicine & international health : TM & IH · 2025Article
- Rapid High-Sensitivity Detection of Antibodies to Trypanosoma cruzi With a Recombinant Tc24 Antigen-Based Magneto-Immunoassay: A Pilot Study.The Journal of infectious diseases · 2025Article
- Comparison of Four Chimeric Antigens and Commercial Serological Assays for the Diagnosis of Trypanosoma cruzi Infection.The American journal of tropical medicine and hygiene · 2025Article
- Evaluation of chimeric recombinant antigens for the serodiagnosis of Trypanosoma cruzi in dogs: a promising tool for Chagas disease surveillance.Parasites & vectors · 2024Article
- Comprehensive Study of the IBMP ELISA IgA/IgM/IgG COVID-19 Kit for SARS-CoV-2 Antibody Detection.Diagnostics (Basel, Switzerland) · 2024Article
- IgG Isotypes Targeting a Recombinant Chimeric Protein of Trypanosoma cruzi in Different Clinical Presentations of Chronic Chagas Disease.The American journal of tropical medicine and hygiene · 2024Article
- Recombinant proteins as promising antigens applied to the immunodiagnosis of Chagas disease: a scoping review.Frontiers in microbiology · 2024Article
- Assessment of Cross-Reactivity of ChimericDiagnostics (Basel, Switzerland) · 2023Article
- Seroepidemiological Survey of Chronic Chagas Disease in a Rural Community in Southern Bahia, Brazil, Using Recombinant Chimeric Antigens.Pathogens (Basel, Switzerland) · 2023Article
- Challenges and Opportunities in Clinical Diagnostic Routine of Envenomation Using Blood Plasma Proteomics.Toxins · 2023Review
- A multicenter comparative study of the performance of four rapid immunochromatographic tests for the detection of anti-Frontiers in medicine · 2023Article
- Western blot using Trypanosoma cruzi chimeric recombinant proteins for the serodiagnosis of chronic Chagas disease: A proof-of-concept study.PLoS neglected tropical diseases · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe performance of current serologic tests for diagnosing chronic Chagas disease (CD) is highly variable. The search for new diagnostic markers has been a constant challenge for improving accuracy and reducing the number of inconclusive results. METHODOLOGY/PRINCIPAL
findingsHere, four chimeric proteins (IBMP-8.1 to -8.4) comprising immunodominant regions of different Trypanosoma cruzi antigens were tested by enzyme-linked immunosorbent assay. The proteins were used to detect specific anti-T. cruzi antibodies in the sera of 857 chagasic and 689 non-chagasic individuals to evaluate their accuracy for chronic CD diagnosis. The antigens were recombinantly expressed in Escherichia coli and purified by chromatographic methods. The sensitivity and specificity values ranged from 94.3% to 99.3% and 99.4% to 100%, respectively. The diagnostic odds ratio (DOR) values were 6,462 for IBMP-8.1, 3,807 for IBMP-8.2, 32,095 for IBMP-8.3, and 283,714 for IBMP-8.4. These chimeric antigens presented DORs that were higher than the commercial test Pathozyme Chagas. The antigens IBMP-8.3 and -8.4 also showed DORs higher than the Gold ELISA Chagas test. Mixtures with equimolar concentrations were tested in order to improve the diagnosis accuracy of negative samples with high signal and positive samples with low signal. However, no gain in accuracy was observed relative to the individual antigens. A total of 1,079 additional sera were used to test cross-reactivity to unrelated diseases. The cross-reactivity rates ranged from 0.37% to 0.74% even for Leishmania spp., a pathogen showing relatively high genome sequence identity to T. cruzi. Imprecision analyses showed that IBMP chimeras are very stable and the results are highly reproducible. CONCLUSIONS/SIGNIFICANCE: Our findings indicate that the IBMP-8.4 antigen can be safely used in serological tests for T. cruzi screening in blood banks and for chronic CD laboratory diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.